entertainment -WSS

entertainment

author：Wikipedia 2025-09-03 11:45:17 - browse：71747

Illumina, the largest maker of DNA-sequencing technology and a storied name in the biotechnology industry, named Jacob Thaysen, a 10-year-veteran at life sciences-tools firm Agilent, as its new CEO.

The appointment follows a bitter board fight that ended with the departure of Francis deSouza, who had been Illumina’s CEO since 2016. The battle, tipped off by Illumina’s troubled acquisition of cancer diagnostics firm Grail, had involved a proxy fight staged by activist investor Carl Icahn.

During the battle, there had been speculation that Jay Flatley, deSouza’s predecessor, could return. Under Flatley, Illumina had grown from an upstart to the dominant player in a field that has proved pivotal for medical research and delivered sizable returns to investors.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

knowledge

WSS

Test for long Covid? Researchers find new clue in blood samples

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Parkinson’s finding may lead to tests and, someday, treatments

Private equity deals in Medicare Advantage declines

A disappointing year of Humira biosimilars

The dental labor crisis is a moment of opportunity

entertainment

entertainment

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Test for long Covid? Researchers find new clue in blood samples

Peter Hotez and the public health issue of online harassment

Independent physicians launch a new lobbying group

What does generative AI mean for health care? We asked experts

Dewpoint Therapeutics lays off staff after losing partnerships

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

George Santos makes 1st court appearance after pleading not guilty to 13 counts

To avoid data mishandling cases, universities eye AI and other tools

knowledge

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Medical mystery: When a cough is not just a cough

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Biotech venture capitalists face new demands from investors

NIH director takes cautious approach to Biden drug pricing priority

Medical mystery: When a cough is not just a cough

hotspot

knowledge

entertainment

knowledge